Vanda Pharmaceuticals Inc. (VNDA) News
Filter VNDA News Items
VNDA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VNDA News Highlights
- For VNDA, its 30 day story count is now at 3.
- Over the past 3 days, the trend for VNDA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DRUG and SAFE are the most mentioned tickers in articles about VNDA.
Latest VNDA News From Around the Web
Below are the latest news stories about VANDA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate VNDA as an investment opportunity.
Calculating The Fair Value Of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)Key Insights Using the 2 Stage Free Cash Flow to Equity, Vanda Pharmaceuticals fair value estimate is US$4.84 Vanda... |
Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY® (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple SclerosisVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has acquired U.S. and Canadian rights to PONVORY® (ponesimod) from Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company. PONVORY® is approved by the U.S. Food and Drug Administration (FDA) and Health Canada to treat adults with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. PONVORY® has a proven safe |
Vanda (VNDA) Rises as FDA Accepts NDA for Gastroparesis DrugThe FDA accepts Vanda's (VNDA) new drug application ("NDA") for tradipitant for treating the symptoms of gastroparesis. The company's shares rise in after-hours trading. |
Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of GastroparesisVanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of Vanda's New Drug Application (NDA) for tradipitant for the treatment of symptoms of gastroparesis. |
One Analyst Thinks Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Revenues Are Under ThreatThe analyst covering Vanda Pharmaceuticals Inc. ( NASDAQ:VNDA ) delivered a dose of negativity to shareholders today... |
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2023 Earnings Call TranscriptVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2023 Earnings Call Transcript November 8, 2023 Vanda Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $0.00238, expectations were $-0.04. Operator: Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today. At this time, I would like to welcome everyone […] |
Vanda Pharmaceuticals Announces Participation at November 2023 Investor ConferencesVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in November 2023: |
Q3 2023 Vanda Pharmaceuticals Inc Earnings CallQ3 2023 Vanda Pharmaceuticals Inc Earnings Call |
Vanda Pharmaceuticals Inc (VNDA) Faces Revenue Decline Amid Generic Competition in Q3 2023Financial and Operational Results Highlighted by Pipeline Progress and Regulatory Updates |
Vanda Pharmaceuticals (VNDA) Reports Break-Even Earnings for Q3Vanda (VNDA) delivered earnings and revenue surprises of 100% and 12.78%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? |